Comparison of Pharmacokinetic Parameters and Biodistribution of Full-Size Antibodies and Nanoantibodies Specific to Human PD-L1

IF 0.8 Q3 Engineering

Nanotechnologies in Russia Pub Date : 2025-03-24 DOI:10.1134/S2635167624602742

N. Verlov, O. Shashkova, I. Krutetskaya, L. Terekhina, S. Shatik, A. Pinevich, V. Burdakov, I. Kulakov, T. Shtam, A. Konevega, A. Stanzhevskii, M. Samoilovich

{"title":"Comparison of Pharmacokinetic Parameters and Biodistribution of Full-Size Antibodies and Nanoantibodies Specific to Human PD-L1","authors":"N. Verlov, O. Shashkova, I. Krutetskaya, L. Terekhina, S. Shatik, A. Pinevich, V. Burdakov, I. Kulakov, T. Shtam, A. Konevega, A. Stanzhevskii, M. Samoilovich","doi":"10.1134/S2635167624602742","DOIUrl":null,"url":null,"abstract":"<p>The study of pharmacokinetic parameters and biodistribution of radiopharmaceuticals is the most important stage in the study of their effectiveness and safety for clinical usage. In the present work, a comparative study of <sup>125</sup>I-labeled full-size therapeutic antibodies to human PD-L1 and recombinant single-domain heavy-chain antibodies (VHH) specific to the same biomarker was conducted. A mouse model of the tumor process induced by transplantation of CT26-PD-L1 recombinant cells stably expressing human PD-L1 receptor on their surface was used. The half-life time for VHH was almost 10 times shorter than for full-size antibodies while both pharmaceuticals demonstrated the ability of specific accumulation in CT26-PD-L1 tumor. The route of excretion for both drugs was mainly through urine. An abnormally rapid decrease of VHH concentration in the blood of mice was noted at the first 5 min after the radioconjugate administration.</p>","PeriodicalId":716,"journal":{"name":"Nanotechnologies in Russia","volume":"19 1 supplement","pages":"S210 - S217"},"PeriodicalIF":0.8000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanotechnologies in Russia","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1134/S2635167624602742","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 0

Abstract

The study of pharmacokinetic parameters and biodistribution of radiopharmaceuticals is the most important stage in the study of their effectiveness and safety for clinical usage. In the present work, a comparative study of ¹²⁵I-labeled full-size therapeutic antibodies to human PD-L1 and recombinant single-domain heavy-chain antibodies (VHH) specific to the same biomarker was conducted. A mouse model of the tumor process induced by transplantation of CT26-PD-L1 recombinant cells stably expressing human PD-L1 receptor on their surface was used. The half-life time for VHH was almost 10 times shorter than for full-size antibodies while both pharmaceuticals demonstrated the ability of specific accumulation in CT26-PD-L1 tumor. The route of excretion for both drugs was mainly through urine. An abnormally rapid decrease of VHH concentration in the blood of mice was noted at the first 5 min after the radioconjugate administration.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanotechnologies in Russia NANOSCIENCE & NANOTECHNOLOGY-

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： Nanobiotechnology Reports publishes interdisciplinary research articles on fundamental aspects of the structure and properties of nanoscale objects and nanomaterials, polymeric and bioorganic molecules, and supramolecular and biohybrid complexes, as well as articles that discuss technologies for their preparation and processing, and practical implementation of products, devices, and nature-like systems based on them. The journal publishes original articles and reviews that meet the highest scientific quality standards in the following areas of science and technology studies: self-organizing structures and nanoassemblies; nanostructures, including nanotubes; functional and structural nanomaterials; polymeric, bioorganic, and hybrid nanomaterials; devices and products based on nanomaterials and nanotechnology; nanobiology and genetics, and omics technologies; nanobiomedicine and nanopharmaceutics; nanoelectronics and neuromorphic computing systems; neurocognitive systems and technologies; nanophotonics; natural science methods in a study of cultural heritage items; metrology, standardization, and monitoring in nanotechnology.